论文部分内容阅读
目的探讨小剂量化疗联合粒细胞集落刺激因子治疗复发难治性急性髓系白血病(AML)的疗效和不良反应。方法予阿糖胞苷(Ara-c)10mg·M-2·d-1,皮下注射,每12小时1次,第1～14天,阿克拉霉素(ACLR)10mg·M-·2d-1入液静滴,第1～8天,G-CSF200μg·M-·2d-1,皮下注射,第1～14天。治疗复发难治性急性髓系白血病(其中复发病例4例、难治7例)。观察CR率、PR率和不良反应。结果11例患者获得CR4例、PR4例,总有效率达72.7%。可见中性粒细胞缺乏、血小板减少、继发感染和发热等不良反应。结论CAG方案治疗复发难治性急性髓系白血病缓解率高,副作用轻;安全可靠,临床值得推广。
Objective To investigate the efficacy and adverse reactions of low-dose chemotherapy combined with granulocyte-colony stimulating factor in the treatment of relapsed and refractory acute myeloid leukemia (AML). Methods Ara-c 10 mg · M-2 · d-1 was injected subcutaneously once every 12 hours for the first 1 to 14 days. The acyclovir (ACLR) 10 mg · M-2d- 1 intravenous infusion, the first to 8 days, G-CSF200μg · M- · 2d-1, subcutaneous injection, the first to 14 days. Treatment of relapsed and refractory acute myeloid leukemia (including 4 cases of recurrent and refractory to 7 cases). CR rate, PR rate and adverse reactions were observed. Results 11 patients received CR4 cases, PR4 cases, the total effective rate was 72.7%. Visible neutropenia, thrombocytopenia, secondary infection and fever and other adverse reactions. Conclusion The CAG regimen has a high remission rate and mild side effects in relapse-refractory acute myeloid leukemia. It is safe and reliable and should be clinically worthy of promotion.